These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

24 related articles for article (PubMed ID: 14621634)

  • 1. Protocol adherence and the ability to achieve target haemoglobin levels in haemodialysis patients.
    Chan K; Moran J; Hlatky M; Lafayette R
    Nephrol Dial Transplant; 2009 Jun; 24(6):1956-62. PubMed ID: 19176685
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Anemia management protocols and epoetin alfa administration: an algorithm approach. Case study of the anemic patient.
    Aiello J
    Nephrol Nurs J; 2002 Jun; 29(3):297-300. PubMed ID: 12164081
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Timely correction of anemia at the initiation of dialysis. Case study of the anemic patient.
    Breiterman-White R
    Nephrol Nurs J; 2002 Oct; 29(5):469-72. PubMed ID: 12434453
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Results of the European Survey on Anaemia Management 2003 (ESAM 2003): current status of anaemia management in dialysis patients, factors affecting epoetin dosage and changes in anaemia management over the last 5 years.
    Jacobs C; Frei D; Perkins AC
    Nephrol Dial Transplant; 2005 May; 20 Suppl 3():iii3-24. PubMed ID: 15824128
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Haemoglobin response to subcutaneous versus intravenous epoetin alfa administration in iron-replete haemodialysis patients.
    Leikis MJ; Kent AB; Becker GJ; McMahon LP
    Nephrology (Carlton); 2004 Jun; 9(3):153-60. PubMed ID: 15189176
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Managing the anemia of end-stage renal disease after hospitalization.
    Krishnan M; Adams E
    Nephrol Nurs J; 2004; 31(5):541-4. PubMed ID: 15518256
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Attaining target hemoglobin levels in patients new to dialysis: individualizing therapy based on initial hemoglobin levels.
    Gregory N
    Nephrol Nurs J; 2004; 31(6):672-5. PubMed ID: 15686331
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Should the target hemoglobin for patients with chronic kidney disease treated with erythropoietic replacement therapy be changed?
    Berns JS
    Semin Dial; 2005; 18(1):22-9. PubMed ID: 15663760
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Guidelines for the treatment of anemia in chronic renal failure].
    Triolo G;
    G Ital Nefrol; 2003; 20 Suppl 24():S61-82. PubMed ID: 14666504
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Patients previously transfused or treated with epoetin alfa at low baseline hemoglobin are at higher risk for subsequent transfusion: an integrated analysis of the Canadian experience.
    Quirt I; Kovacs M; Couture F; Turner AR; Noble M; Burkes R; Dolan S; Plante RK; Lau CY; Chang J
    Oncologist; 2006 Jan; 11(1):73-82. PubMed ID: 16401716
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Operationalizing anemia management: organizing the program and coordinating the team.
    Krishnan M; Adams E
    Nephrol Nurs J; 2003 Oct; 30(5):567-70. PubMed ID: 14621634
    [TBL] [Abstract][Full Text] [Related]  

  • 12.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 13.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 14.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 15.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 16.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 17.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 18.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 19.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 20.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 2.